66 results
424B5
STRO
Sutro Biopharma Inc
2 Apr 24
Prospectus supplement for primary offering
4:58pm
, such as the COVID-19 pandemic, on our operations, the receipt and timing of potential regulatory designations, our ability to maintain and recognize
424B5
STRO
Sutro Biopharma Inc
9 Feb 24
Prospectus supplement for primary offering
4:25pm
and clinical trials, collaboration with third parties, the expected impact of pandemics or contagious diseases, such as the COVID-19 pandemic, on our
8-K
EX-99.1
STRO
Sutro Biopharma Inc
8 Jan 24
Results of Operations and Financial Condition
7:31am
of preclinical and clinical trials, and the expected impact of the COVID-19 pandemic on our operations. It is not possible for our management to predict all risks
8-K
EX-99.1
2d5boqy2
10 Aug 23
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
8-K
EX-99.1
efm2m b034j
15 May 23
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
8:01am
8-K
EX-99.1
h0qza qlxb
30 Mar 23
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:32pm
8-K
EX-99.1
pyd5s
8 Nov 22
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
8-K
EX-99.1
i2k4s8ji50x4icmk p6
8 Aug 22
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
4:32pm
8-K
h06g8z
26 Jul 22
Other Events
4:02pm
8-K
EX-99.1
dxpew7l86jttg o6x8
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm
8-K
EX-99.1
vmmo4 nsg
16 Jun 22
Other Events
7:00am